Hansa Medical’s rights issue oversubscribed

Hansa Medical’s rights issue with preferential rights has been subscribed at 137
percent of which 99 percent was subscribed through preferential rights. The
rights issue comprises 3.7 million shares at SEK 10 per share, which brings SEK
37 million to the company before issue expenses. The capital will be used for
Phase II-studies with the drug candidate IdeS during 2014 and 2015.
An extraordinary general meeting held on March 5, 2014, resolved to carry
through a rights issue of at the most 3 704 229 shares with preferential rights
at SEK 10 per share. The subscription period for the offer was between March 25
and April 8.

In total 3 658 875 shares have been subscribed for with preferential rights,
which corresponds to 99 percent of the number of shares issued. In addition, 1
417 323 shares were subscribed for without preferential rights, corresponding to
38 percent of the number of shares issued. Shares being subscribed for without
preferential rights will be assigned according to the principles described in
the prospectus published on March 19, 2014. No rights issue guarantee will be
applied due to the oversubscription of the rights issue.

The rights issue increases the number of Hansa Medical shares with 3 704 229
shares to a total amount of 25 929 603 shares. Following the rights issue, the
share capital amounts to 25 929 603.

Paid subscribed shares, subscribed with preferential rights, is traded under
short name HMED BTA 1 at NASDAQ OMX First North until the end of April when they
will be converted to shares. Paid subscribed shares, subscribed without
preferential rights, will be traded under short name HMED BTA 2 starting at the
end of next week.
For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO Hansa Medical AB (publ)
Mobile: 46 707 17 54 77
E-mail: emanuel.bjorne@hansamedical.com
www.hansamedical.com
Hansa Medical pursues clinical development and commercialization of innovative
pharmaceuticals and diagnostic methods for the benefit of patients with serious
and rare inflammatory diseases. The portfolio includes a marketed diagnostic
product, a drug candidate in clinical development, and a preclinical research
project. Major shareholders are Bo Håkansson via Farstorps Gård AB, and Nexttobe
AB. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic
AB is the company’s Certified Adviser. The information in this press release is
such information that Hansa Medical AB (publ) is obliged to disclose under the
Securities Market Act and/or the Financial Instruments Trading Act. The
information was made public on April 11, 2014 at 08:30 CET.